Skip to content

Sinovac COVID-19 vaccine shows positive effect in elderly volunteers

September 9, 2020

Sinovac Biotech Ltd. (SVA) announces positive preliminary results from a Phase 1/2 clinical trial evaluating the safety and immunogenicity of Coronavac, its COVID-19 vaccine candidate, in healthy adults at least 60 years old.

421 volunteers aged between 60 and 89 were recruited. They received two shots of the vaccine 28 days apart.

Low, medium and high doses were well-tolerated with no vaccine-related serious adverse events reported.

The seroconversion (generation of antibodies) rate and geometric mean titers (GMT) (average level of antibodies in a group) were comparable to those observed in younger adults (aged 18-59) who participated in earlier studies.  Specifically, the seroconversion rate in elderly subjects was 98.0% compared to 97.4% in younger adults. GMTs in the medium dose groups were 42.2 and 44.1, respectively.

Detailed results will be submitted for publication.

The medium dose has been selected for a Phase 3 trial.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: